The Catalyst Calendar: Your Weekly Map of Policy Events That Move Money

Earnings season gets wall-to-wall coverage. Economic data releases move algorithmic traders in milliseconds. But the slower clock of regulatory and legislative calendars — FOMC meeting cycles, FDA approval windows, appropriations deadlines, agency rulemaking timelines — operates on a schedule that is public, often months in advance, and systematically mispriced by investors focused on the next quarter.

The reason is structural. Most retail investors and even many institutional funds are organized around sectors and earnings models, not regulatory exposure. They know a drug company is running a trial. They do not track the PDUFA date — the Prescription Drug User Fee Act deadline by which the FDA must act on a New Drug Application — or understand that a Complete Response Letter arriving instead of an approval can erase half a company's market cap in a morning.

The Catalyst Calendar fills that gap. Each week we surface the scheduled policy events with genuine market-moving potential, explain the mechanism connecting the event to specific tickers, and distinguish between situations where the stock is pricing in a good outcome versus one where the market hasn't yet connected the dots.

One framing we return to constantly: Washington does not set out to enrich shareholders. It sets out to achieve policy goals. The enrichment is a byproduct — and that byproduct is reliably directional if you understand who the policy serves.

The Federal Open Market Committee meets roughly eight times per year on a published schedule. Market participants focus overwhelmingly on the target rate decision and the Fed Chair's press conference. That's the right instinct applied to the wrong variables.

The rate level itself is less important than the trajectory signal — and the trajectory signal's most direct transmission to equities runs through specific business models, not the market as a whole.

Rate-sensitive business models to watch:

Regional banks hold loan portfolios priced at floating rates and fund them with deposits. When the Fed holds or cuts, their net interest margin — the spread between what they earn on loans and what they pay depositors — compresses or expands. Tickers like Regions Financial (RF), Citizens Financial (CFG), and KeyCorp (KEY) move on NIM expectations more than on the headline rate itself. Watch the language in the Fed's statement about the pace of future moves; the path reprices these balance sheets more than the current level.

Mortgage REITs such as Annaly Capital (NLY) and AGNC Investment (AGNC) hold agency mortgage-backed securities funded by short-term borrowing. They are levered bets on the shape of the yield curve. A steepening curve (long rates rising faster than short rates) expands their spread. A flat or inverted curve compresses it. FOMC language about long-end rates — particularly anything touching quantitative tightening or balance sheet policy — hits these names directly.

Homebuilders — D.R. Horton (DHI), Lennar (LEN), PulteGroup (PHM) — are rate proxies through affordability math. The 30-year mortgage rate is driven by the 10-year Treasury yield, which responds to Fed expectations. A 50-basis-point decline in mortgage rates meaningfully expands the qualified buyer pool, directly benefiting order backlogs.

The mechanism to watch this cycle: The Fed has been navigating between a labor market that remains resilient and inflation that has been slow to return to target. Any meeting where the statement language shifts from 'higher for longer' toward explicit rate-cut timing creates immediate relief for the floating-rate borrowers in leveraged loan markets — which matters for Business Development Companies (BDCs) like Ares Capital (ARCC) and Prospect Capital (PSEC) whose portfolio companies carry variable-rate debt.

The FDA operates on a statutory clock. When a pharmaceutical company files a New Drug Application or a Biologics License Application, the agency has a defined window — typically ten to twelve months — to issue a decision. The action date, known as the PDUFA date (for Prescription Drug User Fee Act), is public. The FDA publishes its calendar, analysts track it, and yet the events remain chronically mispriced for a simple reason: binary outcomes are psychologically difficult to hold.

How the mechanism works:

An FDA approval expands a drug's addressable market instantly — from zero (or from whatever it had under compassionate use or prior approvals) to the full commercial launch. The company can now advertise, negotiate formulary placement with pharmacy benefit managers, and build a salesforce around the product. Revenue can go from $0 to hundreds of millions in the first year for a drug entering a large unmet-need market.

A Complete Response Letter (CRL) — the FDA's mechanism for declining to approve while leaving the door open for resubmission — typically requires additional trials, manufacturing remediation, or label negotiations that push commercial launch out by one to three years. The stock effect is often immediate and severe.

An Advisory Committee meeting (ad-com) precedes many PDUFA dates by weeks. When an independent panel of physicians, statisticians, and patient advocates votes on whether benefit outweighs risk, the FDA follows their recommendation the large majority of the time. Ad-com votes are therefore soft previews of the PDUFA outcome and move stocks almost as much as the final decision.

The tickers most exposed to FDA catalysts are mid-cap and small-cap biotechs where a single drug can represent the entire enterprise value. Larger diversified pharma — Pfizer (PFE), Bristol-Myers Squibb (BMY), Merck (MRK) — also have PDUFA dates, but a single approval or rejection is rarely company-defining given their diversified pipelines.

What to look for in upcoming cycles: New drug approvals in oncology (particularly ADCs — antibody-drug conjugates — where the field is competitive and approval in one tumor type sets commercial precedent for others), obesity and metabolic disease (where Eli Lilly (LLY) and Novo Nordisk (NVO) have changed the standard of care and generic/biosimilar competition timelines now matter), and rare disease (where orphan drug designations give companies pricing power and the patient populations make clinical trial success rates more legible).

The U.S. defense budget is not voted on once and forgotten. It moves through a recurring annual cycle — the President's Budget Request in February, markup and authorization through the Armed Services Committees in spring, appropriations through the fall, and a continuing resolution or omnibus if the process stalls — and at each stage specific programs are funded, cut, or restructured.

The mechanism that matters for investors: Defense contractors do not book revenue when Congress appropriates money. They book revenue when the Department of Defense awards a contract, when they achieve program milestones, and when the government accepts delivery. The gap between an appropriation and a contract award can be months or years, which creates a scheduling layer between the legislative event and the income statement.

What does move immediately is backlog and book-to-bill ratios. When a major contract is awarded — a next-generation fighter, a ship program, a missile defense system — it enters the contractor's backlog, which is the single most forward-looking financial metric in defense. Investors price future revenue from backlog. So the contract award announcement, not the budget vote, is the immediate stock catalyst.

Key names by segment:

Large platform contractors: Lockheed Martin (LMT), RTX Corporation (RTX), Northrop Grumman (NOC), and General Dynamics (GD) derive revenue from multi-decade programs — the F-35, various missile systems, submarines — where production rate decisions in the Pentagon's budget directly affect quarterly unit deliveries and margins.

Cybersecurity and software-defined defense: Palantir (PLTR) and Booz Allen Hamilton (BAH) win on government IT modernization and intelligence contracts. Continuing resolutions (when Congress fails to pass a budget and agencies operate on prior-year funding) hurt these firms disproportionately because new program starts are blocked; only ongoing programs continue.

Ammunition and munitions replenishment: The draw-down of U.S. stockpiles sent to support allies has created a sustained demand signal for manufacturers like General Dynamics's ordnance division and Olin Corporation (OLN), which makes propellant for small-caliber ammunition. The supplemental appropriations that fund foreign military assistance flow through domestic production, not foreign procurement.

The continuing resolution trap: When Congress fails to pass the defense authorization bill on time and operates on a CR, defense contractors face a specific problem — new program starts are prohibited, and existing contracts can only be funded at prior-year rates. This creates a lumpy revenue pattern that punishes companies heavily dependent on new contract awards in the current fiscal year. Watch the October 1 deadline and track whether appropriations are moving.

Tariffs are a tax. They are collected at the border by Customs and Border Protection and paid by the importer of record — which is almost always an American company, not the foreign exporter. Whether that tax gets passed to consumers as higher prices, absorbed as margin compression, or redirected toward domestic sourcing is a corporate finance decision made in real time by individual companies, and the outcomes vary dramatically by industry, product type, and competitive structure.

The mechanism: A tariff on imported steel raises input costs for any American manufacturer that uses steel — automakers, appliance companies, industrial equipment producers. Simultaneously, it raises the cost of competing imports, which gives domestic steel producers pricing power. This is not a metaphor; it is the intended policy transmission.

U.S. Steel (X), Cleveland-Cliffs (CLF), and Nucor (NUE) are direct beneficiaries when tariffs are imposed or maintained on imported flat-rolled steel. Their foreign competitors face a price disadvantage in the American market. Domestic producers can either hold price and widen margin or take volume from imports. Both outcomes improve earnings.

Automotive: Ford (F) and General Motors (GM) source significant quantities of components from Mexico and Canada under USMCA rules of origin. Tariff changes on auto parts or finished vehicles alter make-versus-buy decisions for every model program and are reflected in guidance. Both companies provide tariff exposure disclosures in earnings calls that make the math explicit.

Consumer electronics and retail: Apple (AAPL) assembles the majority of its iPhone units in China. A tariff increase on consumer electronics from China creates a direct cost-of-goods-sold problem unless Apple accelerates its announced diversification to India and Vietnam — a process that takes years, not quarters. Similarly, large importers like Walmart (WMT) and Target (TGT) face tariff exposure on private-label goods sourced from Asia.

The pharmaceutical supply chain: The U.S. imports a substantial share of active pharmaceutical ingredients from China and India. An executive order or tariff action targeting pharmaceutical imports would raise production costs for domestic manufacturers that rely on foreign API suppliers. This is a category where tariff announcements move broadly across the generic drug sector — Viatris (VTRS), Amneal Pharmaceuticals (AMRX) — before the specifics are understood.

What to watch for in trade policy cycles: The mechanism that connects a tariff announcement to a stock move is rarely immediate and clean. The market initially reacts to the headline. The actual earnings impact plays out over one to four quarters as inventory turns and new sourcing decisions are implemented. This lag creates opportunities for investors who understand the supply chain well enough to separate the signal from the noise.

The Catalyst Calendar publishes weekly, keyed to the actual policy calendar. Each edition will:

Name the events on the near-term horizon — FOMC decisions, ad-com votes, budget deadlines, agency rulemaking comment periods, trade negotiation milestones. These dates are derived from public government sources: the Federal Reserve's published meeting schedule, the FDA's PDUFA tracker, Congressional calendars, and agency regulatory agendas.

Explain the mechanism, not just the ticker. The column will tell you why a specific event affects a specific company's income statement, balance sheet, or competitive position. Understanding the mechanism lets you evaluate whether the market has already priced the event and whether the expected outcome is the right one to anchor to.

Distinguish between confirmed catalysts and probabilistic ones. A PDUFA date is a hard deadline — the FDA must act by that date. A tariff announcement from a trade negotiation is probabilistic — it depends on political will, reciprocal actions, and legal constraints. The column will be explicit about where on that spectrum each event falls.

What this column does not do: We do not predict specific regulatory outcomes. We do not tell you to buy or sell specific securities. We do not fabricate contract numbers, clinical trial results, or government data. Everything here is grounded in public information and durable economic mechanisms, not rumor or invented specifics.

Money Racket's thesis is simple: Washington moves money. Your job is to understand the map before the move is announced, not after it hits the wire.